このエントリーをはてなブックマークに追加
ID 16580
Eprint ID
16580
フルテキストURL
93_519.pdf 940 KB
タイトル(別表記)
Clinical Studies on Chemotherapy for Multiple Myeloma Part II: Response rates, prognostic factors, and side effects in multiple myeloma treated with MIP (Prednisolone and sequential Melphalan and Ifosfamide).
著者
足立 富郎 岡山大学第二内科
抄録
This report consists of an analysis of 47 patients with multiple myeloma registered between October, 1975, and December, 1980. All of them received Prednisolone together with sequential Melphalan and Ifosfamide (MIP). Clinical studies of the response rates and prognostic factors were conducted and side effects and complications in the treatment of MIP were discussed. The results are summarized as follows: 1. The response rates to MIP therapy as shown by marked diminishment of plasmacytoma and decrease of bone marrow plasmacytosis below 10 per cent were slightly lower than in M, MP, or I therapy. In MIP therapy, the frequency of over 50% reduction of the pretreatment value of M-protein level was 59.6% and the frequency of marked improvement in symptomatic disability was 52.9%. In conclusion, MIP therapy seemed to be better overall in comparison to M, MP, and I. 2. The 50% survival time in 47 patients treated with MIP followed from the initiation of treatment was 19 months. 3. In MIP therapy, the response rate (shown by the reduction of M-protein level) was paradoxically higher in all clinical parameters in the advanced stage group than in the early and intermittent stages. This study made clear the relationship between the survival time and patients characteristics. Of clinical parameters, (1) age, (2) stage IV in the clinical staging of Durie and Salmon, (3) hypercalcemia, (4) extensive bone lytic lesions, and (5) type IV in the patho-morphological stage of Brucher correlated with progressive life span shortage. 5. Patients who responded rapidly (i.e. within 5 weeks) had a longer duration of remission and longer survival than those who responded slowly (6-16 weeks). 6. In stage III, patients who received MIP had a higher response rate and longer survival than those who received M+MP. 7. Side effects and complications reported during MIP treatment were as follows: 1. Bone marrow suppression (Granulocyte≦1000/cmm in 11 cases) 2. Liver damage(GPT≧200 u. in 3 cases) 3. Respiratory infection (in 10 cases) 4. Urinary infection (in 3 cases) 5. Herpes zoster (in 4 cases with IgG-peak) 6. Lung fibrosis (in 2 cases with IgG-peak)
キーワード
多発性骨髄腫
予後因子
多剤併用療法
発行日
1981-06-30
出版物タイトル
岡山医学会雑誌
出版物タイトル(別表記)
Journal of Okayama Medical Association
93巻
5-6号
出版者
岡山医学会
出版者(別表記)
Okayama Medical Association
開始ページ
519
終了ページ
536
ISSN
0030-1558
NCID
AN00032489
資料タイプ
学術雑誌論文
オフィシャル URL
https://www.jstage.jst.go.jp/article/joma1947/93/5-6/93_5-6_519/_article/-char/ja/
関連URL
http://www.okayama-u.ac.jp/user/oma/index.html
言語
日本語
著作権者
岡山医学会
論文のバージョン
publisher
査読
有り
Eprints Journal Name
joma
過去1年のアクセス数
アクセス数 : ?
ダウンロード数 : ?

今月のアクセス数
アクセス数 : ?
ダウンロード数 : ?